Larimar Therapeutics
LRMR
49 hedge funds and large institutions have $157M invested in Larimar Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 10 closing their positions.
0.27% more ownership
Funds ownership: 81.99% → 82.26% (+0.27%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
6% less capital invested
Capital invested by funds: $167M → $157M (-$10.3M)
9% less funds holding
Funds holding: 54 → 49 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2.67M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.74M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$1.05M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$698K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.57M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.01M |
| 3 |
BC
BIT Capital
Berlin,
Germany
|
-$1.08M |
| 4 |
Renaissance Technologies
New York
|
-$595K |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$403K |
LRMR Hedge Fund Activity: Q4 2021 in Review
49 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2021, worth a combined $157M — down 6.2% from $167M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LRMR and 5 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $2.67M. The largest seller was Citadel Advisors, exiting entirely with an estimated $3.57M sold.
- 49 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2021, down from 54 in Q3 2021.
- Funds reported $157M of Larimar Therapeutics stock for Q4 2021, down 6.2% quarter-over-quarter.
- 5 funds opened new Larimar Therapeutics positions in Q4 2021 and 10 closed out, a net change of -5 holders.
- The largest Larimar Therapeutics buyer in Q4 2021 was Mangrove Partners, an estimated $2.67M added.
- The largest Larimar Therapeutics seller in Q4 2021 was Citadel Advisors, an estimated $3.57M sold.
Based on aggregated 13F filings for Q4 2021.